Genomenon to Participate in BIO Partnering at JPM During J.P. Morgan Week 2023
Executive team to reveal hidden costs of incomplete genomic information for orphan drug discovery, development, and commercialization
ANN ARBOR, Mich., Jan. 5, 2023 /PRNewswire-PRWeb/ -- Genomenon, Inc., an AI-driven genomics company, announced today that it will participate in BIO Partnering at JPM, January 9-12, 2023 in San Francisco.
Details of the event are as follows:
Event: BIO Partnering @ JPM
Date: January 9-12, 2023
Registration: https://www.bio.org/events/bio-partnering-jpm/registration
Members of the Genomenon leadership team will be available to participate in one-on-one meetings with registered pharmaceutical companies and investors to raise awareness of the cost of incomplete genomic information at every stage in the drug discovery process for rare disease therapeutics. To schedule a meeting with the Genomenon team, please reach out through the BIO Partnering system.
About Genomenon
Genomenon is an AI-driven genomics company focused on making genomic information actionable for patients with rare genetic diseases and cancer. Keeping pace with the ever-evolving body of knowledge within genomics, Genomenon connects current research with patient DNA to accelerate clinical decision-making and pharmaceutical drug discovery.
For more information, visit Genomenon.com
About BIO
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the U.S. and in more than 30 other nations.
BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.
For more information, visit http://www.bio.org
Media Contact
Candace Chapman, Genomenon, +1-734-794-3075 x708, [email protected]
SOURCE Genomenon
Share this article